While previous reports on Endostatin for the treatment of lung adenocarcinoma combined with malignant pleural fluid have mostly been in combination with AP chemotherapy regimens or TKI, this case explored the clinical efficacy of PD‐L1 inhibitors in combination with endostatin and dual anti‐targeted therapy. Here, COL18A1 is linked to lung adenocarcinoma.